Fidelis Capital Partners LLC Acquires 256 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Fidelis Capital Partners LLC grew its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 8.9% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 3,139 shares of the medical research company’s stock after buying an additional 256 shares during the period. Fidelis Capital Partners LLC’s holdings in Thermo Fisher Scientific were worth $1,666,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. Savant Capital LLC grew its stake in shares of Thermo Fisher Scientific by 0.5% during the fourth quarter. Savant Capital LLC now owns 3,627 shares of the medical research company’s stock valued at $1,997,000 after purchasing an additional 18 shares during the last quarter. Sugarloaf Wealth Management LLC raised its holdings in shares of Thermo Fisher Scientific by 6.9% during the fourth quarter. Sugarloaf Wealth Management LLC now owns 294 shares of the medical research company’s stock worth $156,000 after acquiring an additional 19 shares during the period. Rosenberg Matthew Hamilton raised its holdings in shares of Thermo Fisher Scientific by 3.7% during the fourth quarter. Rosenberg Matthew Hamilton now owns 526 shares of the medical research company’s stock worth $279,000 after acquiring an additional 19 shares during the period. Tsfg LLC increased its stake in Thermo Fisher Scientific by 8.3% in the 4th quarter. Tsfg LLC now owns 249 shares of the medical research company’s stock valued at $132,000 after buying an additional 19 shares during the last quarter. Finally, 1776 Wealth LLC increased its stake in Thermo Fisher Scientific by 2.4% in the 4th quarter. 1776 Wealth LLC now owns 799 shares of the medical research company’s stock valued at $440,000 after buying an additional 19 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the sale, the senior vice president now directly owns 12,901 shares in the company, valued at approximately $7,250,362. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the sale, the senior vice president now owns 12,901 shares of the company’s stock, valued at approximately $7,250,362. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Debora L. Spar sold 164 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $546.97, for a total value of $89,703.08. Following the transaction, the director now owns 1,207 shares in the company, valued at approximately $660,192.79. The disclosure for this sale can be found here. In the last ninety days, insiders sold 50,277 shares of company stock valued at $28,513,384. 0.32% of the stock is owned by insiders.

Thermo Fisher Scientific Trading Down 1.0 %

Shares of NYSE:TMO traded down $5.47 on Thursday, hitting $541.78. 2,075,782 shares of the company’s stock were exchanged, compared to its average volume of 1,547,352. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $603.82. The stock has a market capitalization of $206.80 billion, a price-to-earnings ratio of 34.94, a price-to-earnings-growth ratio of 2.33 and a beta of 0.80. The business’s 50 day simple moving average is $571.57 and its two-hundred day simple moving average is $527.01. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.75 and a quick ratio of 1.39.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, topping analysts’ consensus estimates of $5.64 by $0.03. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The business had revenue of $10.89 billion during the quarter, compared to the consensus estimate of $10.73 billion. During the same period in the previous year, the company posted $5.40 earnings per share. The firm’s revenue was down 4.9% on a year-over-year basis. Analysts anticipate that Thermo Fisher Scientific Inc. will post 21.52 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were paid a $0.39 dividend. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a yield of 0.29%. The ex-dividend date of this dividend was Thursday, March 14th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.10%.

Wall Street Analyst Weigh In

A number of analysts have issued reports on TMO shares. The Goldman Sachs Group boosted their price objective on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. Raymond James increased their target price on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a research note on Thursday, February 1st. HSBC increased their target price on shares of Thermo Fisher Scientific from $630.00 to $660.00 and gave the company a “buy” rating in a report on Wednesday. Sanford C. Bernstein restated a “market perform” rating on shares of Thermo Fisher Scientific in a report on Monday, January 8th. Finally, Evercore ISI raised their price objective on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a research report on Thursday, April 4th. Five analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $604.69.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.